How should we manage a patient with a first episode of optic neuritis who is negative for neuromyelitis optica antibodies but positive for myelin oligodendrocyte glycoprotein antibodies?

Management of First-Episode MOG-Positive Optic Neuritis

For a patient with first-attack optic neuritis who is MOG-positive and NMO-negative, treat acutely with high-dose intravenous methylprednisolone (1 gram daily for 3-5 days) followed by a slow oral steroid taper, and strongly consider initiating maintenance immunosuppression given the high relapse risk in MOG-associated disease.

Acute Phase Treatment

The immediate priority is aggressive immunosuppression to preserve vision and prevent irreversible optic nerve damage 1, 2, 3.

First-Line Acute Therapy

• Intravenous methylprednisolone: 1 gram daily for 3-5 days 2, 3, 4
• Follow with oral prednisone taper over 4-8 weeks 1, 3
  • Critical: MOG-EM patients are particularly prone to flare-ups during rapid steroid withdrawal 1
  • Taper slowly (e.g., 1 mg/kg/day initially, reducing by 10 mg weekly, then 5 mg weekly below 20 mg)

Steroid-Refractory Cases

If no improvement after 3-5 days of IV steroids or vision continues to deteriorate 2, 3:

• Plasma exchange (PLEX): 5-7 exchanges over 10-14 days 1, 2, 3
  • MOG-positive patients show particularly good response to antibody-depleting therapies 1
• IVIG: Alternative if plasma exchange unavailable 1, 2, 3

Critical pitfall: Delaying immunosuppressive treatment beyond 2 weeks significantly worsens visual outcomes 4, 5. Do not adopt a "wait and see" approach.

Disease Classification and Prognosis

This patient has MOG-IgG-associated encephalomyelitis (MOG-EM), a distinct entity from both MS and AQP4-positive NMOSD 1. Key distinguishing features:

• MOG-EM follows a relapsing course in most adult cases 1
• Unlike MS, MOG-EM may be ineffective or worsened by some MS disease-modifying therapies 1
• Visual prognosis is generally better than AQP4-positive NMOSD but worse than MS-associated optic neuritis 2, 6
• Recurrent optic neuritis is the most common presentation in adults 1

Maintenance Immunosuppression Decision

The critical decision point: Should this first-attack patient receive long-term immunosuppression?

Strong Indications for Maintenance Therapy

Initiate maintenance treatment if ANY of the following 1, 3:

• Severe visual loss (worse than 20/200)
• Bilateral involvement
• Optic disc edema with chiasmal involvement
• Steroid-dependent (symptoms flare during taper) 1, 5
• Additional CNS lesions on MRI suggesting higher relapse risk
• High MOG-IgG titers (>1:2560) 1

Maintenance Treatment Options

First-line choices 1, 3:

1. Rituximab (preferred for relapsing disease)

   • 1000 mg IV at weeks 0 and 2, then every 6 months
   • Best evidence for preventing relapses in MOG-EM 1, 3
   • Monitor B-cell counts; retreat when CD19+ cells return

2. IVIG (especially effective in MOG-EM)

   • 2 g/kg monthly 1, 2, 3
   • Particularly useful in children but effective in adults 1

3. Mycophenolate mofetil

   • 1000-1500 mg twice daily 3, 4
   • Alternative if rituximab unavailable

4. Azathioprine

   • 2-3 mg/kg/day 3, 5
   • Less expensive option but potentially less effective than rituximab

Avoid in MOG-EM 1:

• Interferon-beta (may worsen disease)
• Fingolimod (reports of worsening)
• Natalizumab (insufficient evidence, potential harm)

Monitoring Strategy

Short-term (First 6-12 months)

• Repeat MOG-IgG testing at 6-12 months 1
  • If antibodies disappear, disease may be monophasic (though rare in adults)
  • Persistent positivity strongly predicts relapsing course 1
• Monthly clinical assessments during steroid taper
• MRI brain and orbits at 3-6 months to assess for new lesions

Long-term

• Clinical follow-up every 3-6 months
• Annual brain/spine MRI if on maintenance therapy
• OCT monitoring for subclinical RNFL thinning 4, 5
• Visual field testing every 6 months

Special Considerations

If patient remains monophasic after first attack:

• Continue close monitoring without maintenance therapy is reasonable IF:
  • MOG-IgG becomes negative on repeat testing 1
  • Complete visual recovery
  • No new lesions on follow-up MRI
  • No steroid-dependency during taper

However, recognize that second attacks can occur years later 1, so maintain high vigilance.

Red flags requiring immediate re-evaluation 1:

• New visual symptoms
• Myelitis symptoms (weakness, sensory level, bladder dysfunction)
• Brainstem symptoms
• Encephalopathy

The evidence strongly supports that MOG-positive optic neuritis is NOT simply "typical MS optic neuritis" and requires a distinct therapeutic approach prioritizing antibody-targeted therapies and careful steroid management to optimize long-term visual outcomes 1, 2, 6, 3.